companies developing glp-1 receptor agonists GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Structure and properties of GLP‐1

Description

GLP-1 exerts pleiotropic effects on innate and adaptive immune responses, endothelial function, and adipose tissue inflammation, thereby influencing multiple pathways relevant to psoriatic disease (8)

In addition, the GLP-1 can inhibit postprandial gastric emptying and reduce gastric acid secretion, inhibit gastric and duodenal peristalsis by inhibiting vagus nerve, and increase the pressure of pylorus, thus reducing appetite, causing a reduction in body weight and participating in the so-called ileal braking effect (35)

Weeks 11-12: Reaching the Milestone By the end of month 3, the adaptation phase is essentially complete

These innovative biologics have revolutionized diabetes management by offering superior glycemic control alongside significant weight loss benefits, positioning them as preferred treatment options over traditional therapies